Good afternoon :)
Place Order
Add to Watchlist

Sun Pharmaceutical Industries Ltd

SUNPHARMA Share Price

1,789.000.83% (-14.90)

SUNPHARMA Share Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
LargecapWith a market cap of ₹4,32,816 cr, stock is ranked 14
Low RiskStock is 1.37x as volatile as Nifty

SUNPHARMA Stock Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
LargecapWith a market cap of ₹4,32,816 cr, stock is ranked 14
Low RiskStock is 1.37x as volatile as Nifty

SUNPHARMA Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
37.856.450.75%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
50.696.470.52%

SUNPHARMA Analyst Ratings & Forecast

Detailed Forecast 
88%
Analysts have suggested that investors can buy this stock

from 34 analysts

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

SUNPHARMA Company Profile

Sun Pharmaceutical Industries Limited is a pharmaceuticals company which offers generics, branded generics, specialty products, over-the-counter products, anti-retroviral and APIs.

Investor Presentation

View older 

Mar 4, 2025

PDF
View Older Presentations

SUNPHARMA Similar Stocks (Peers)

Compare with peers 
PE Ratio
30.41
1Y Return
10.98%
Buy Reco %
72.73
PE Ratio
67.94
1Y Return
23.77%
Buy Reco %
68.00
PE Ratio
56.06
1Y Return
8.38%
Buy Reco %
81.25
PE Ratio
17.91
1Y Return
0.87%
Buy Reco %
46.67
PE Ratio
50.18
1Y Return
33.17%
Buy Reco %
61.76
Compare with Peers
SUNPHARMA Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly

SUNPHARMA Stock Summary · February 2025

Sun Pharma is experiencing robust growth, particularly in its specialty segment, with a notable 14% increase in its India business, driven by branded generics and new product launches. However, the company faces significant operational hurdles due to regulatory compliance issues, particularly with FDA inspections affecting several facilities, which could hinder future product introductions. While lower distribution costs and a focus on emerging markets present opportunities, pricing pressures in the generic market, especially in Japan, pose challenges. The management is strategically adjusting R&D expenditures and enhancing market readiness through an expanded field force, aiming to leverage its competitive edge in pain management and specialty products despite ongoing uncertainties in revenue recognition and market dynamics.

Key Points on Sunpharma Stock
SUNPHARMA Stock Growth Drivers
6
  • Strong Financial Performance

    In Q3 FY '25, Sun Pharma reported significant financial growth, with sales reaching INR 40,090

  • Market Leadership and Growth in India

    Sun Pharma maintained its position as the leading company in the Indian pharmaceutical market, achieving

SUNPHARMA Stock Challenges
5
  • Decline in U.S. Sales

    In Q3 FY25, Sun Pharma's U.S. sales decreased by approximately 1% year-over-year, totaling US$ 474

  • Regulatory Compliance Issues

    The company is currently facing compliance issues, with several facilities down with the FDA. Concerns

SUNPHARMA Forecasts

Price

Revenue

Earnings

SUNPHARMA

Income

Balance Sheet

Cash Flow

SUNPHARMA Income Statement

Industry refers to the sub-sector this company belongs to.
Higher than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 10.64%, vs industry avg of 9.04%

Decreasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 13.7% to 13.08%

Higher than Industry Net Income
Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 29.15%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue29,145.2832,201.5927,328.2230,091.4033,489.0934,357.3139,729.9644,520.2049,887.1753,560.61
Raw Materialssubtract6,724.158,402.377,193.988,302.088,929.609,328.3010,459.1511,349.0710,370.4837,429.56
Power & Fuel Costsubtract545.44525.09559.97613.60621.89627.09702.78830.05760.78
Employee Costsubtract4,772.314,902.305,367.055,967.096,362.356,862.237,300.838,296.039,429.06
Selling & Administrative Expensessubtract5,219.205,224.614,727.005,350.336,995.376,283.417,366.889,482.3611,033.19
Operating & Other expensessubtract3,752.782,434.803,983.833,739.603,214.786,235.537,147.912,452.834,410.66
Depreciation/Amortizationsubtract1,037.531,264.751,499.841,753.252,052.782,079.952,143.742,529.432,556.642,561.96
Interest & Other Itemssubtract523.24399.80517.57555.25302.73141.43127.35172.00238.47255.79
Taxes & Other Itemssubtract2,024.922,083.501,383.281,144.781,244.66-104.451,208.59934.851,511.511,879.56
EPS20.3028.988.7311.1115.6912.1013.6435.3239.9147.65
DPS1.003.502.002.754.007.5010.0011.5013.5013.50
Payout ratio0.050.120.230.250.250.620.730.330.340.28

SUNPHARMA Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2015

Annual report

PDF

Investor Presentation

Mar 25PDF
FY 2022

Annual report

PDF

Investor Presentation

Mar 24PDF
FY 2023

Annual report

PDF

Investor Presentation

Apr 28PDF
Jan 16PDF
Sep 16PDF
FY 2024

Annual report

PDF

Investor Presentation

Sep 11PDF
Jul 21PDF
FY 2025

Annual Report Pending

Investor Presentation

Mar 4PDF
Nov 28PDF
Sep 30PDF
 

SUNPHARMA Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Sun Pharmaceutical Industries Ltd45.206.450.75%
Cipla Ltd30.414.680.84%
Torrent Pharmaceuticals Ltd67.9416.410.84%
Mankind Pharma Ltd56.0611.20

SUNPHARMA Stock Price Comparison

Compare SUNPHARMA with any stock or ETF
Compare SUNPHARMA with any stock or ETF
SUNPHARMA
Loading...

SUNPHARMA Shareholdings

SUNPHARMA Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

SUNPHARMA Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

SUNPHARMA Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding54.48%12.21%6.48%17.96%8.87%

Jun 2024

Sep 2024

Dec 2024

Mar 2025

SUNPHARMA Shareholding History

Dec '23MarJunSepDec '24Mar17.07%17.72%17.23%18.02%18.05%17.96%

Mutual Funds Invested in SUNPHARMA

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Sun Pharmaceutical Industries Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
0.4768%4.16%-0.75%7/102 (-2)
0.4138%2.73%-0.27%11/98 (0)
0.3718%3.90%-0.26%6/211 (0)

Compare 3-month MF holding change on Screener

SUNPHARMA Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing SUNPHARMA stock

A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Sun Pharmaceutical Industries Ltd

Loading...
Pharma Tracker

Pharma Tracker

Created by Windmill Capital

SUNPHARMA's Wtg.
11.65%
CAGR
15.32%

SUNPHARMA Events

SUNPHARMA Dividend Trend

Increasing Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year

SUNPHARMA has increased dividends consistently over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.75%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹7.55 every year

Dividends

Corp. Actions

Announcements

Legal Orders

SUNPHARMA Upcoming Dividends

No upcoming dividends are available

SUNPHARMA Past Dividends

Cash Dividend

Ex DateEx DateFeb 6, 2025

Interim
Interim | Div/Share: ₹10.50

Dividend/Share

10.50

Ex DateEx Date

Feb 6, 2025

Cash Dividend

Ex DateEx DateJul 12, 2024

Final
Final | Div/Share: ₹5.00

Dividend/Share

5.00

Ex DateEx Date

Jul 12, 2024

Cash Dividend

Ex DateEx DateFeb 9, 2024

Interim
Interim | Div/Share: ₹8.50

Dividend/Share

8.50

Ex DateEx Date

Feb 9, 2024

Cash Dividend

Ex DateEx DateJul 28, 2023

Final
Final | Div/Share: ₹4.00

Dividend/Share

4.00

Ex DateEx Date

Jul 28, 2023

Cash Dividend

Ex DateEx DateFeb 8, 2023

Interim
Interim | Div/Share: ₹7.50

Dividend/Share

7.50

Ex DateEx Date

Feb 8, 2023

SUNPHARMA Stock News & Opinions

Corporate
Sun Pharma and Israel-based Moebius Medical publish two articles on MM-II

Sun Pharmaceutical Industries and Israel-based Moebius Medical announced today the publication of two articles in Osteoarthritis and Cartilage, the official journal of the Osteoarthritis Research Society International (OARSI), highlighting MM-II, a novel non-opioid product for the treatment of symptomatic knee osteoarthritis. MM-II is based on a proprietary suspension of large, empty, multilamellar liposomes designed to reduce joint friction and wear, thereby alleviating pain. The two publications offer complementary insights into MM-II's clinical efficacy and mechanism of action, underscoring its potential therapeutic value. The first publication presents results from a Phase 2b randomized, double-blind, placebo-controlled trial (NCT04506463), which enrolled 397 patients across the US, Europe and Asia. Findings demonstrate that a single injection of MM-II provided clinically meaningful pain relief through 26 weeks, with a favorable safety and tolerability profile. The second publication, titled 'Empty large liposomes reduce cartilage degeneration in osteoarthritic rats by forming a lubricative coating,' details MM-II's unique mechanism of action. The research shows that MM-II forms a lubricative layer over cartilage surfaces, reducing friction and slowing cartilage degeneration. The authors suggest that the results of the clinical trial may be mediated through the coating of the cartilage surfaces, though additional mechanisms may contribute to the long term pain reduction seen in Phase 2b study. 'The data from these publications show that MM-II has the potential to provide durable pain relief for patients,' said Prof. Thomas J Schnitzer, MD, PhD, a rheumatologist and professor of Medicine at Northwestern University and lead author of the clinical trial manuscript. 'With limited treatment options, lack of novel treatment approaches, and concerns around opioid use, MM-II may offer a promising alternative to hyaluronic acid and steroid treatments.' Powered by Capital Market - Live

1 day agoCapital Market - Live
Corporate
Sun Pharma receives favourable ruling in preliminary injunction delaying launch of LEQSELVI'

Sun Pharmaceutical Industries announced that on 09 April 2025, the U.S. Court of Appeals for the Federal Circuit held an oral argument on the Company's appeal of the U.S. District Court for the District of New Jersey's decision that previously granted a preliminary injunction delaying the Company's launch of LEQSELVI' (deuruxolitinib) in the United States. Shortly after the oral argument concluded, on 09 April 2025, the U.S. Court of Appeals for the Federal Circuit ruled in favour of the Company and vacated the preliminary injunction effective immediately. While the litigation between Incyte Corporation and the Company continues, the preliminary injunction is no longer in effect. The Company is no longer under a court order that delays or restricts the Company from launching LEQSELVI'. The Company will disclose LEQSELVI' launch plans in due course of time.Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Spotlight
Sun Pharma launches Fexuprazan tablets 40 mg in India

The drug, available in 40 mg tablets, is approved as a new treatment for adults with erosive esophagitis of all grades. FEXUCLUE, containing Fexuprazan, is primarily used to treat acid-related disorders, including gastroesophageal reflux disease (GERD) and erosive esophagitis. It is also being studied for the prevention of NSAID-induced peptic ulcers and gastritis. Sun Pharma has obtained the rights from Daewoong Pharmaceutical, a South Korean biopharmaceutical company, to manufacture and commercialize FEXUCLUE in India. As part of the agreement, Daewoong will receive upfront and milestone payments, as well as royalties. Kirti Ganorkar, CEO of India Business, Sun Pharma, said, 'Erosive esophagitis is a serious condition that greatly affects patients' quality of life. Despite available treatments, there remains a significant unmet need in its management. FEXUCLUE is a best-in-class treatment option with the potential to bridge this gap. At Sun Pharma, we are committed to introducing innovative medicines that enhance patients' quality of life. Sun Pharmaceuticals Industries is a leading global pharmaceutical company with a specialty and generic presence and India's top pharma company. The pharma major's consolidated net profit increased 15.04% to Rs 2,903.38 crore on a 10.46% rise in revenue from operations to Rs 13,675.46 crore in Q3 FY25 over Q3 FY24. Shares of Sun Pharmaceuticals Industries fell 3.47% to Rs 1,650 on the BSE.Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Sun Pharmaceutical launches Fexuprazan tablets 40 mg in India

Sun Pharmaceutical Industries has launched Fexuprazan tablets 40 mg in India under the brand name 'FEXUCLUE''. FEXUCLUE', a novel potassium competitive acid blocker (PCAB), is approved as a new treatment for adults with Erosive Esophagitis of all grades. Sun Pharma has obtained rights from Daewoong Pharmaceutical Co Ltd, Korea, a biopharmaceutical company, to manufacture and commercialise FEXUCLUE'(Fexuprazan) in India. As per agreement terms, Daewoong will be entitled to upfront and milestone payments, including royalties.Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Sun Pharma completes acquisition of Antibe Therapeutics Inc., Canada

Sun Pharmaceutical Industries has completed 100% acquisition of Antibe Therapeutics Inc., Canada for a total consideration of CAD 4.5 million. Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Sun Pharma gains as arm acquires Antibe Therapeutics for $4.5 Million

Sun Pharmaceuticals Industries is a leading global pharmaceutical company with a specialty and generic presence and India's top pharma company. The pharma major's consolidated net profit increased 15.04% to Rs 2,903.38 crore on a 10.46% rise in revenue from operations to Rs 13,675.46 crore in Q3 FY25 over Q3 FY24Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Sun Pharmaceuticals Industries Ltd soars 0.96%, gains for fifth straight session

Sun Pharmaceuticals Industries Ltd rose for a fifth straight session today. The stock is quoting at Rs 1699.6, up 0.96% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.31% on the day, quoting at 22466.9. The Sensex is at 74002.67, up 0.24%. Sun Pharmaceuticals Industries Ltd has dropped around 0.12% in last one month. Meanwhile, Nifty Pharma index of which Sun Pharmaceuticals Industries Ltd is a constituent, has dropped around 1.58% in last one month and is currently quoting at 20386.85, up 1.23% on the day. The volume in the stock stood at 14.7 lakh shares today, compared to the daily average of 22.43 lakh shares in last one month. The benchmark March futures contract for the stock is quoting at Rs 1699.9, up 0.91% on the day. Sun Pharmaceuticals Industries Ltd is up 8.17% in last one year as compared to a 1.86% gain in NIFTY and a 9.69% gain in the Nifty Pharma index.The PE of the stock is 128.24 based on TTM earnings ending December 24.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Sun Pharmaceuticals Industries Ltd rises for third straight session

Sun Pharmaceuticals Industries Ltd is up for a third straight session today. The stock is quoting at Rs 1673.25, up 1.08% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.71% on the day, quoting at 22337.55. The Sensex is at 73661.95, down 0.59%. Sun Pharmaceuticals Industries Ltd has slipped around 4.19% in last one month. Meanwhile, Nifty Pharma index of which Sun Pharmaceuticals Industries Ltd is a constituent, has slipped around 5.49% in last one month and is currently quoting at 20332.1, down 0.4% on the day. The volume in the stock stood at 11.98 lakh shares today, compared to the daily average of 22.91 lakh shares in last one month. The benchmark March futures contract for the stock is quoting at Rs 1674.7, up 1.07% on the day. Sun Pharmaceuticals Industries Ltd is up 7.36% in last one year as compared to a 1.54% jump in NIFTY and a 8.67% jump in the Nifty Pharma index.The PE of the stock is 126.1 based on TTM earnings ending December 24.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Sun Pharma to acquire 100% stake in Nasdaq-listed Checkpoint Therapeutics

Checkpoint is a Nasdaq-listed commercial-stage company focused on developing novel treatments for patients with solid tumor cancers. For the nine-month period ending September 2024, Checkpoint reported $0.04 million in revenue and a net loss of $27.3 million. Checkpoint has received approval from the U.S. Food & Drug Administration (FDA) for UNLOXCYT (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Cutaneous Squamous Cell Carcinoma (cSCC) is the second-most common type of skin cancer in the United States, with an estimated annual incidence of approximately 1.8 million cases according to the Skin Cancer Foundation. As per the terms of the contract, Sun Pharma will acquire all outstanding shares of Checkpoint and Checkpoint stockholders will receive, for each share of common stock they hold, an upfront cash payment of $4.10, without interest, and a non-transferable contingent value right (CVR) entitling the stockholder to receive up to an additional $0.70 in cash, without interest, if cosibelimab is approved prior to certain deadlines in the European Union pursuant to the centralized approval procedure or in Germany, France, Italy, Spain or the United Kingdom, subject to the terms and conditions in the contingent value rights agreement. The upfront cash payment of $4.10 per share of common stock represents a premium of approximately 66.0% to Checkpoint's closing share price on March 7, 2025, the last trading day prior to today's announcement. In connection with the transaction, Checkpoint, Sun Pharma and Fortress Biotech, Inc., Checkpoint's controlling stockholder, have entered into a royalty agreement, under which following the closing of the transaction Fortress would be entitled to receive royalty payments based on future sales of cosibelimab during a specified term, in lieu of royalty rights that were granted to Fortress in connection with its founding of Checkpoint. The transaction is expected to be completed in the second calendar quarter of 2025. Dilip Shanghvi, chairman & managing director of Sun Pharma, said: 'Combining UNLOXCYT, an FDA approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma, with Sun Pharma's global presence means patients with cSCC may soon have access to an important, new treatment option. The acquisition further bolsters our innovative portfolio in onco-derm therapy.' Sun Pharmaceuticals Industries is a leading global pharmaceutical company with a specialty and generic presence and India's top pharma company. The pharma major's consolidated net profit increased 15.04% to Rs 2,903.38 crore on 10.46% rise in revenue from operations to Rs 13,675.46 crore in Q3 FY25 over Q3 FY24. The scrip was down 0.06% to currently trade at Rs 1609 on the BSE. Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Sun Pharma to acquire Nasdaq-listed Checkpoint Therapeutics

Sun Pharmaceutical Industries and Checkpoint Therapeutics, Inc. (Nasdaq: CKPT) (Checkpoint) today announced that they have entered into an agreement by which Sun Pharma will acquire Checkpoint, an immunotherapy and targeted oncology company. Checkpoint is a Nasdaq-listed commercial-stage company focused on developing novel treatments for patients with solid tumor cancers. Checkpoint has received approval from the U.S. Food & Drug Administration (FDA) for UNLOXCYT' (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Upon completion of the transaction, Sun Pharma will acquire all outstanding shares of Checkpoint and Checkpoint stockholders will receive, for each share of common stock they hold, an upfront cash payment of $4.10, without interest, and a non-transferable contingent value right (CVR) entitling the stockholder to receive up to an additional $0.70 in cash, without interest, if cosibelimab is approved prior to certain deadlines in the European Union pursuant to the centralized approval procedure or in Germany, France, Italy, Spain or the United Kingdom, subject to the terms and conditions in the contingent value rights agreement. The upfront cash payment of $4.10 per share of common stock represents a premium of approximately 66.0% to Checkpoint's closing share price on 07 March 2025, the last trading day prior to today's announcement. The transaction is expected to be completed in the second calendar quarter of 2025. The transaction is subject to customary closing conditions, including required regulatory approvals and approval by the holders of a majority of the voting power of outstanding shares of Checkpoint common stock, and by the holders of a majority of the shares of Checkpoint common stock that are not held by Fortress or by certain other affiliates of Checkpoint. For the nine-month period ending September 2024, Checkpoint reported $0.04 million in revenue and a net loss of $27.3 million. The R&D expense for the nine-month period was $19.3 million. As of September 30, 2024, Checkpoint had a cash balance of $4.7 million, outstanding accounts payable and accrued expenses of $15.6 million, and outstanding accounts payable and accrued expenses -related party of $2.0 million. In connection with the transaction, Fortress, which holds a majority of Checkpoint's outstanding voting power, has agreed to vote in favor of the transaction.Powered by Capital Market - Live

1 month agoCapital Market - Live

Frequently asked questions

  1. What is the share price of Sun Pharmaceutical Industries Ltd (SUNPHARMA) today?

    The share price of SUNPHARMA as on 25th April 2025 is ₹1789. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Sun Pharmaceutical Industries Ltd (SUNPHARMA) share?

    The past returns of Sun Pharmaceutical Industries Ltd (SUNPHARMA) share are
    • Past 1 week: 5.35%
    • Past 1 month: -1.23%
    • Past 3 months: -1.00%
    • Past 6 months: -2.43%
    • Past 1 year: 21.41%
    • Past 3 years: 95.06%
    • Past 5 years: 271.52%

  3. What are the peers or stocks similar to Sun Pharmaceutical Industries Ltd (SUNPHARMA)?

    The peers or stocks similar to Sun Pharmaceutical Industries Ltd (SUNPHARMA) include:

  4. What is the dividend yield % of Sun Pharmaceutical Industries Ltd (SUNPHARMA) share?

    The current dividend yield of Sun Pharmaceutical Industries Ltd (SUNPHARMA) is 0.75.

  5. What is the market cap of Sun Pharmaceutical Industries Ltd (SUNPHARMA) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sun Pharmaceutical Industries Ltd (SUNPHARMA) is ₹432816.04 Cr as of 25th April 2025.

  6. What is the 52 week high and low of Sun Pharmaceutical Industries Ltd (SUNPHARMA) share?

    The 52-week high of Sun Pharmaceutical Industries Ltd (SUNPHARMA) is ₹1960.35 and the 52-week low is ₹1377.20.

  7. What is the PE and PB ratio of Sun Pharmaceutical Industries Ltd (SUNPHARMA) stock?

    The P/E (price-to-earnings) ratio of Sun Pharmaceutical Industries Ltd (SUNPHARMA) is 45.20. The P/B (price-to-book) ratio is 6.45.

  8. Which sector does Sun Pharmaceutical Industries Ltd (SUNPHARMA) belong to?

    Sun Pharmaceutical Industries Ltd (SUNPHARMA) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  9. How to buy Sun Pharmaceutical Industries Ltd (SUNPHARMA) shares?

    You can directly buy Sun Pharmaceutical Industries Ltd (SUNPHARMA) shares on Tickertape. Simply sign up, connect your demat account and place your order.